Physician profile
Edgar P Toscano
NPI 1972532042
$1,679.10
in general payments reported to CMS, 2019-2025
12 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $212 · 2021: $75.29 · 2022: $240 · 2023: $215 · 2024: $361 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738 · Education: $38.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.65 |
| Education | $38.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $517.86 | 2019-2024 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $327.91 | 2021-2024 | |
| Ardelyx, INC. | $205.05 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Glaxosmithkline, LLC. | $130.97 | 2023 | Jesduvroq, Benlysta |
| Travere Therapeutics, INC. | $124.55 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $95.51 | 2020 | |
| Fresenius USA Marketing, INC. | $94.22 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $66.04 | 2021-2023 | Farxiga |
| Calliditas Therapeutics US INC. | $46.59 | 2023-2025 | Tarpeyo |
| Vifor Pharma, INC. | $24.71 | 2020 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Opko Pharmaceuticals, LLC | $21.08 | 2025 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Toscano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.